RBRussell D. Bradford

Russell D. Bradford

*This is an algorithmically generated author record based on publicly available information.

Russell D. Bradford has a total of 51 co-authors. Here are the top co-authors by number of shared publications:

  • Stipan Jonjic

    Faculty of Medicine, University of Rijeka, 51000 Rijeka, Croatia

    3 shared publications
  • Ester Pernjak Pugel

    Department of Histology and Embryology, Faculty of Medicine, University of Rijeka, Rijeka, Croatia

    2 shared publications
  • Mijo Golemac

    Department of Histology and Embryology, Faculty of Medicine, University of Rijeka, Rijeka, Croatia

    2 shared publications
  • William J. Britt

    Department of Histology and Embryology, Faculty of Medicine, University of Rijeka, Croatia,1 Department of Pediatrics, University of Alabama Birmingham, Birmingham, Alabama,2 Hematopoiesis Unit, Nikolaus Fiebiger Institute for Molecular Medicine, University Erlangen-Nürnberg, Erlangen, Germany,3 Institute for Clinical and Molecular Virology, University Hospital Erlangen, Erlangen, Germany4

    2 shared publications
  • William J. Britt

    Department of Pediatrics, Microbiology, and Neurobiology, Heersink School of Medicine, UAB, Birmingham, USA

    2 shared publications
  • Đurđica Cekinović

    Clinic for Infectious Diseases, Clinical Hospital Centre Rijeka, 51000 Rijeka, Croatia

    2 shared publications

Latest Publications

  • Open Access

    Questions in self‐selection studies used in consumer research for nonprescription drug candidates: Limitations and recommendations

    by Eric P. Brass, Russell D. Bradford, Arthur Stone

    Self‐selection studies assess participants' ability to use label information to decide if a proposed nonprescription drug is appropriate for their use. The optimal use of information from participants' responses in these trials has not been studied. Data from a self‐selection study for a progestogen‐only contraceptive pill (norgestrel 0.075 mg tablets, Opill) were analyzed. Participants (1772 evaluable participants) were provided with the proposed drug facts label and asked sequentially: (1) Given what you have read on the label and your own health history, is this product okay or not okay for you to take home today and start to use?; (2) Why or why not?; (3) Would you like to purchase Opill today to take home for your own use?; (4) Why or why not? The Per Guidance Analysis based on the US Food and Drug Administration's Guidance considered only the response to the first question as defining a selector. The Complete Analysis considered the responses to all four questions to determine a selector. The Per Guidance Analysis characterized 1597 participants as selectors, whereas the Complete Analysis identified 1180 participants as selectors. The decrease in selectors reflected participants who responded “okay” to the initial question but “no” to purchase question while providing rational explanations for their shift in responses. The results support the use of all available information when assessing a participant's intent in self‐selection studies for nonprescription drug candidates. The findings are discussed in the context of findings from the social cognitive and communication sciences.


  • Open Access

    Adherence among a cohort taking progestin-only pills prescribed by a healthcare provider: Results of the BENCHMARK study

    by Russell D. Bradford, Sarah J. Farnsworth, Irene Laurora, Stephanie Sober, Hélène Guillard, Anna Glasier, Saul Shiffman


  • Open Access

    Murine CMV-Induced Hearing Loss Is Associated with Inner Ear Inflammation and Loss of Spiral Ganglia Neurons

    by Russell D. Bradford, Young-Gun Yoo, Mijo Golemac, Ester Pernjak Pugel, Stipan Jonjic, William J. Britt

    Congenital human cytomegalovirus (HCMV) occurs in 0.5–1% of live births and approximately 10% of infected infants develop hearing loss. The mechanism(s) of hearing loss remain unknown. We developed a murine model of CMV induced hearing loss in which murine cytomegalovirus (MCMV) infection of newborn mice leads to hematogenous spread of virus to the inner ear, induction of inflammatory responses, and hearing loss. Characteristics of the hearing loss described in infants with congenital HCMV infection were observed including, delayed onset, progressive hearing loss, and unilateral hearing loss in this model and, these characteristics were viral inoculum dependent. Viral antigens were present in the inner ear as were CD3+ mononuclear cells in the spiral ganglion and stria vascularis. Spiral ganglion neuron density was decreased after infection, thus providing a mechanism for hearing loss. The lack of significant inner ear histopathology and persistence of inflammation in cochlea of mice with hearing loss raised the possibility that inflammation was a major component of the mechanism(s) of hearing loss in MCMV infected mice. Congenital infection with human cytomegalovirus (HCMV) is the most common viral infection of the fetus and occurs in 0.5–2.0% of all live births in most regions in the world. Infection of the fetus can result in a spectrum of end-organ disease, including long term damage to the central nervous system (CNS). Although less than 10% of infected infants exhibit clinical evidence of end-organ disease, up to 10% of the total number of infected infants develop hearing loss. Mechanisms of disease leading to hearing loss are poorly understood because of the limited availability of pathological specimens and accessibility of the inner ear. Existing small animal models fail to recapitulate many features of this infection of the inner ear. In this report we describe a mouse model in which newborn animals infected peripherally with murine CMV develop hearing loss following hematogenous spread of virus to the inner ear. Hearing loss occurs in 30–50% of animals and characteristics of hearing loss in infants with congenital HCMV infection, including delayed onset of hearing loss, progressive hearing loss, and unilateral hearing loss were present in infected mice. Our findings suggest that host derived inflammatory responses and not direct virus-mediated cytopathology are responsible for hearing loss. Findings from this study provide insight into potential mechanisms of hearing loss in infants with congenital HCMV infection.


  • Open Access

    Herpes Simplex Encephalitis during Treatment with Tumor Necrosis Factor–α Inhibitors

    by Russell D. Bradford, April C. Pettit, Patty W. Wright, Mark J. Mulligan, Larry W. Moreland, David A. McLain, John W. Gnann, Karen C. Bloch

    We report 3 cases of herpes simplex virus encephalitis in patients receiving tumor necrosis factor-alpha (TNF-α) inhibitors for rheumatologic disorde


  • Passive Immunization Reduces Murine Cytomegalovirus-Induced Brain Pathology in Newborn Mice

    by Đurđica Cekinović, Mijo Golemac, Ester Pernjak Pugel, Jelena Tomac, Luka ČiČiN-ŠaIn, Irena Slavuljica, Russell Bradford, Sonja Misch, Thomas H. Winkler, Michael Mach, et al.

    Human cytomegalovirus (HCMV) is the most frequent cause of congenital viral infections in humans and frequently leads to long-term central nervous system (CNS) abnormalities that include learning disabilities, microcephaly, and hearing loss. The pathogenesis of the CNS infection has not been fully elucidated and may arise as a result of direct damage of CMV-infected neurons or indirectly secondary to inflammatory response to infection. We used a recently established model of mouse CMV (MCMV) infection in newborn mice to analyze the contribution of humoral immunity to virus clearance from the brain. In brains of MCMV-infected newborn mice treated with immune serum, the titer of infectious virus was reduced below detection limit, whereas in the brains of mice receiving control (nonimmune) serum significant amounts of virus were recovered. Moreover, histopathological and immunohistological analyses revealed significantly less CNS inflammation in mice treated with immune serum. Treatment with MCMV-specific monoclonal antibodies also resulted in the reduction of virus titer in the brain. Recipients of control serum or irrelevant antibodies had more viral foci, marked mononuclear cell infiltrates, and prominent glial nodules in their brains than mice treated with immune serum or MCMV-specific antibodies. In conclusion, our data indicate that virus-specific antibodies have a protective role in the development of CNS pathology in MCMV-infected newborn mice, suggesting that antiviral antibodies may be an important component of protective immunological responses during CMV infection of the developing CNS.


  • CD8+ T Lymphocytes Control Murine Cytomegalovirus Replication in the Central Nervous System of Newborn Animals

    by Glenn R. B. Bantug, Djurdijca Cekinovic, Russell Bradford, Thad Koontz, Stipan Jonjic, William J. Britt

    Human CMV infection of the neonatal CNS results in long-term neurologic sequelae. To define the pathogenesis of fetal human CMV CNS infections, we investigated mechanisms of virus clearance from the CNS of neonatal BALB/c mice infected with murine CMV (MCMV). Virus titers peaked in the CNS between postnatal days 10–14 and infectious virus was undetectable by postnatal day 21. Congruent with virus clearance was the recruitment of CD8+ T cells into the CNS. Depletion of CD8+ T cells resulted in death by postnatal day 15 in MCMV-infected animals and increased viral loads in the liver, spleen, and the CNS, suggesting an important role for these cells in the control of MCMV replication in the newborn brain. Examination of brain mononuclear cells revealed that CD8+ T cell infiltrates expressed high levels of CD69, CD44, and CD49d. IE1168-specific CD8+ T cells accumulated in the CNS and produced IFN-γ and TNF-α but not IL-2 following peptide stimulation. Moreover, adoptive transfer of brain mononuclear cells resulted in decreased virus burden in immunodepleted MCMV-infected syngeneic mice. Depletion of the CD8+ cell population following transfer eliminated control of virus replication. In summary, these results show that functionally mature virus-specific CD8+ T cells are recruited to the CNS in mice infected with MCMV as neonates.


  • Congenital Cytomegalovirus Infection: Association between Virus Burden in Infancy and Hearing Loss

    by Suresh B. Boppana, Karen B. Fowler, Robert F. Pass, Lisa B. Rivera, Russell D. Bradford, Fred D. Lakeman, William J. Britt


  • Open Access

    Detection of Cytomegalovirus (CMV) DNA by Polymerase Chain Reaction Is Associated with Hearing Loss in Newborns with Symptomatic Congenital CMV Infection Involving the Central Nervous System

    by Russell D. Bradford, Gretchen Cloud, Alfred D. Lakeman, Suresh Boppana, David W. Kimberlin, Richard Jacobs, Gail Demmler, Pablo Sanchez, William Britt, Seng‐Jaw Soong, et al.

    Objective. The study sought to determine the relationship between cytomegalovirus (CMV) viremia during early infancy and clinical and laboratory outcom


  • Open Access

    Long-Range Mapping of the Streptococcus agalactiae Phylogenetic Lineage Restriction Digest Pattern Type III-3 Reveals Clustering of Virulence Genes

    by John F. Bohnsack, April A. Whiting, Russell D. Bradford, Brenna K. Van Frank, Shinji Takahashi, Elisabeth E. Adderson

    Human isolates of serotype III Streptococcus agalactiae (group B streptococcus [GBS]) can be divided into three separate phylogenetic lineages based on analysis of the restriction digest patterns (RDPs) of chromosomal DNA. Nine DNA sequences that are present in all isolates of the RDP III-3 phylogenetic lineage, but not in the other lineages, were identified by genomic subtractive hybridization. A complete physical map of a III-3 chromosome was constructed. Six of the nine III-3-specific sequences mapped to a 340-kb Sse 8387I fragment which contains or is located close to known GBS virulence genes. One of the III-3-specific probes, AW-10, encodes part of GBSi1, a group II intron that is inserted at two sites within the GBS genome. The second chromosomal site for GBSi1 was isolated, sequenced, and mapped to a location near the locus responsible for hemolysin production. These findings suggest that the genetic variation that distinguishes the RDP type III-3 strains from other serotype III strains occurs largely within localized areas of the genome containing known or putative virulence genes.